Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 4/20 | 0.44 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CASP7 | P55210 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5471124 | 0.98 | ALDH1A1 (0.62) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| Hydrochloric Acid SCHEMBL25310447 | 0.98 | ALDH1A1 (0.62) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL6787637 | 0.82 | HTR7 (0.54) | ALDH1A1KDM4ETAAR1USP2CASP1 | |
| Hydrochloric Acid SCHEMBL20293632 | 0.81 | HTR7 (0.52) | ALDH1A1KDM4ETAAR1USP2CASP1 | |
| Hydrochloric Acid SCHEMBL6786943 | 0.81 | HTR7 (0.52) | ALDH1A1KDM4ETAAR1USP2CASP1 | |
| SCHEMBL24126297 | 0.80 | SIGMAR1 (0.46) | KDM4ECYP1A2CYP2C9SIGMAR1HTR1A | |
| SCHEMBL23458786 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL5102919 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL25255051 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL7991455 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007522-B1 | 2- 4-[4-(4,5-DICHLORO-2-METHYLIMIDAZOL-1-YL)BUTYL]PIPERAZIN-1-YL -5-FLUOROPYRIMIDINE, ITS PREPARATION AND THERAPEUTIC USE | ESTEVE LABOR DR (ES) | 2002-11-20 | — | — | EP | claimed |
| CN-1094491-C | 2- {4- [4- (4, 5-dichloro-2-methylimidazol-1-yl) butyl ] -1-piperazinyl } -5-fluoropyrimidine, process for its preparation and its use | ESTEVE LABOR DR (ES) | 2002-11-20 | — | — | CN | claimed |
| US-6346620-B1 | DEHYDROHALOGEN WITH AMINATION IN THE PRESENCE OF POTASSIUM CARBONATE IN APROTIC SOLVENT | LABORATORIES DEL DR. ESTEVE S.A. (ES) | 2002-02-12 | — | — | US | claimed |
| CN-1261888-A | 2{4-[4-(4,5-dichloro-2-methylimidazol-1-yl) butyl]-1-piperazinyl}-5-fluoropyrimiding, preparation and therapeutic use | ESTEVE LABOR DR (ES) | 2000-08-02 | — | — | CN | claimed |
| EP-1007522-A1 | 2- 4-[4-(4, 5-DICHLORO -2-METHYLIMIDAZOL-1-YL) BUTYL]-1-PIPERAZINYL -5-FLUOROPYRIMIDINE,PREPARATION AND THERAPEUTIC USE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-06-14 | — | — | EP | claimed |
| WO-1998055476-A1 | 2-{4-[4-(4,5-DICHLORO-2- METHYLIMIDAZOL-1-YL)BUTYL] -1-PIPERAZINYL}-5-FLUOROPYRIMIDINE, PREPARATION AND THERAPEUTIC USE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1998-12-10 | — | — | WO | claimed |
| EP-3630779-B1 | ANTIBIOTIC RESISTANCE BREAKERS | KING S COLLEGE LONDON (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| WO-2024137329-A1 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4265621-A1 | PYRROLE DERIVATIVE, AND PREPARATION METHOD AND USE THEREFOR | Shenzhen Sungening Bio-Medical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-109982704-B | Pharmaceutical preparation | F2G有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-4818756-A | CENTRAL NERVOUS SYSTEM DISORDERS | TROPONWERKE GMBH & CO., KG (DE) | 1989-04-04 | — | — | US | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4605655-A | NEUROLEPTIC AGENTS; NO MOVEMENT DISORDER SIDE EFFECTS | BRISTOL-MYERS COMPANY (US) | 1986-08-12 | — | — | US | disclosed |
| US-4581357-A | Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound | MEAD JOHNSON & COMPANY (US) | 1986-04-08 | — | — | US | disclosed |
| US-4581357-A | Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound | MEAD JOHNSON & COMPANY (US) | 1986-04-08 | — | — | US | disclosed |
| EP-0129128-A2 | 2-Pyrimidinyl-1-piperazine derivatives, process for their preparation and medicines containing them | Troponwerke GmbH & Co. KG (DE) | 1984-12-27 | — | — | EP | disclosed |
| US-4423049-A | TRANQUILIZERS | MEAD JOHNSON & COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | ALDH1A1 2181/4885KDM4E 3028/4885TAAR1 4558/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | ALDH1A1 1033/4885KDM4E 929/4885TAAR1 4273/4885 |
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | ALDH1A1 481/4885KDM4E 3599/4885TAAR1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.